Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resmetirom in Well-compensated NASH Cirrhosis
NCT05500222Phase 3Active, not recruiting
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of resmetirom in Nonalcoholic steatohepatitis (NASH), Cirrhosis, sponsored by Madrigal Pharmaceuticals. Started Aug 2022; status: active, not recruiting.
02
Drugs
resmetirom
03
Conditions
Nonalcoholic steatohepatitis (NASH)Cirrhosis
Beyond the preview
Go deeper on NCT05500222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05500222.